Scholarlink

Purpose <p>Immunotherapy has emerged as a promising treatment for metastatic triple-negative breast cancer (mTNBC), yet factors influencing its adoption remain unclear. This study examines clinical, sociodemographic, and facility-related determinants of immunotherapy use in mTNBC patients using the National Cancer Database (NCDB).</p> Methods <p>We conducted a retrospective cohort study of mTNBC patients from the NCDB (2015–2020), categorizing them into immunotherapy recipients and non-recipients. Patients with missing data on key variables were excluded. Univariable and multivariable logistic regression identified factors influencing immunotherapy adoption. Cox proportional hazards regression and log-rank tests assessed overall survival.</p> Results <p>Among 1,887 mTNBC patients, 232 (12.2%) received immunotherapy. Factors positively associated with immunotherapy use included later diagnosis year (2018–2020: OR 5.35, p &lt; 0.001), academic facilities (OR 1.43, p = 0.044), and private insurance (OR 1.34, p &lt; 0.001). Lower likelihood of immunotherapy use was observed in older age (71+: OR 0.49, p = 0.019), rural facilities (OR 0.43, p = 0.042), Black race (OR 0.73, p = 0.039), Hispanic ethnicity (OR 0.53, p = 0.026), and higher Charlson comorbidity scores (≥ 2: OR 0.31, p = 0.035). Immunotherapy was associated with significantly improved survival (median 2.21 vs. 1.01&#xa0;years, log-rank p &lt; 0.001) and reduced mortality risk (HR 0.59, p &lt; 0.001).</p> Conclusion <p>Immunotherapy use in mTNBC has increased in recent years, with clinical, sociodemographic, and facility-related factors influencing its adoption. Our findings highlight the importance of addressing disparities in access to immunotherapy to ensure equitable treatment and better survival outcomes for all mTNBC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical, sociodemographic, and facility-related determinants of immunotherapy use in metastatic triple-negative breast cancer

  • 期刊论文

  • 发表日期：

    2025年5月15日

查看全文
  • Ismail Ajjawi,
  • Alejandro Rios,
  • Wei Wei,
  • Tristen S. Park,
  • Maryam B. Lustberg

摘要

Purpose

Immunotherapy has emerged as a promising treatment for metastatic triple-negative breast cancer (mTNBC), yet factors influencing its adoption remain unclear. This study examines clinical, sociodemographic, and facility-related determinants of immunotherapy use in mTNBC patients using the National Cancer Database (NCDB).

Methods

We conducted a retrospective cohort study of mTNBC patients from the NCDB (2015–2020), categorizing them into immunotherapy recipients and non-recipients. Patients with missing data on key variables were excluded. Univariable and multivariable logistic regression identified factors influencing immunotherapy adoption. Cox proportional hazards regression and log-rank tests assessed overall survival.

Results

Among 1,887 mTNBC patients, 232 (12.2%) received immunotherapy. Factors positively associated with immunotherapy use included later diagnosis year (2018–2020: OR 5.35, p < 0.001), academic facilities (OR 1.43, p = 0.044), and private insurance (OR 1.34, p < 0.001). Lower likelihood of immunotherapy use was observed in older age (71+: OR 0.49, p = 0.019), rural facilities (OR 0.43, p = 0.042), Black race (OR 0.73, p = 0.039), Hispanic ethnicity (OR 0.53, p = 0.026), and higher Charlson comorbidity scores (≥ 2: OR 0.31, p = 0.035). Immunotherapy was associated with significantly improved survival (median 2.21 vs. 1.01 years, log-rank p < 0.001) and reduced mortality risk (HR 0.59, p < 0.001).

Conclusion

Immunotherapy use in mTNBC has increased in recent years, with clinical, sociodemographic, and facility-related factors influencing its adoption. Our findings highlight the importance of addressing disparities in access to immunotherapy to ensure equitable treatment and better survival outcomes for all mTNBC patients.